From August 29th to 31st 2025, Guo Lab at Shenzhen Bay Laboratory (SZBL) convened a focused symposium on PET molecular imaging for early Alzheimer’s disease (AD) diagnosis and clinical translation, bringing together a myriad of experts to discuss the biomarker value of PET tracers (including Aβ and tau, among others), key technical bottlenecks, and pathways to accelerate real-world clinical implementation and multimodal integration. As a part of the academic exchange visit program , the event also fostered deeper cross-institutional dialogue on translational molecular imaging and its role in precision medicine for neurodegenerative disease. 

        The symposium agenda on August 30th 2025 featured several thematic talks spanning methodological advances, clinical neuroimaging, and cohort-based translational research: 

        Welcome & Introduction — SZBL overview and opening remarks hosted by Dr. Tengfei Guo. 

        Recent Advances in PET Neuroimaging — Presented by Dr. Richard Carson from Yale University. 

        PET Imaging of Neurodegeneration — Presented by Dr. Yihui Guan from Huashan Hospital, Fudan University. 

        Innovation and Translation of Advanced PET Molecular Imaging Technologies — Presented by Dr. Qiyu Peng.

        The Greater Bay Area Healthy Aging Brain Study (GHABS) — Local cohort and translational study update Given by Dr. Tengfei Guo. 

        To strengthen hands-on exchange and collaboration, the event also included on-site visits and discussion sessions, including a tour of SZBL/SMART (Weiguang site), a visit to the Department of Nuclear Medicine at the Seventh Affiliated Hospital of Sun Yat-sen University, lab visits, and extended roundtable discussion. 

        Beyond the main symposium day on August 30th, the broader exchange visit on Aug 29th and Sep 1st was designed around three interconnected themes: PET imaging for early AD diagnosis and intervention strategie; translational molecular imaging bridging research and clinical practice (including standardization and adoption barriers); and integrating PET with complementary modalities (e.g., MRI and fluid biomarkers) to inform early detection and therapeutic decision-making. 

        By connecting leading expertise in PET neuroimaging with SZBL’s ongoing efforts in cohort building and translational biomarker research, the symposium hosted by Guo Lab advanced shared priorities in early detection, clinical translation, and multimodal precision approaches for Alzheimer’s disease.